Fulcrum Therapeutics Inc (FULC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $287.96M
Last updated: Nov 17, 2026 at 11:05 AM ET
Fulcrum Therapeutics Inc (FULC) Competitors
The companies most similar to Fulcrum Therapeutics are X4 Pharmaceuticals (XFOR), Prelude Therapeutics (PRLD) and Fennec Pharmaceuticals (FENC). By market cap, Fulcrum Therapeutics ranks 8th of the 13 companies on this page; Phathom Pharmaceuticals (PHAT) is the largest at $492.63M.
Peer Comparison
FULC's revenue growth of -100.0% is below the peer median of 4.6%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| X4 Pharmaceuticals Inc (XFOR) | $318.59M | N/A | 21.7x | 0.0% | -36.9% | 63.1% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| Fennec Pharmaceuticals Inc (FENC) | $410.25M | 159.5x | 6.8x | 3.0% | N/A | 57.3% | 0.00% |
| Phathom Pharmaceuticals Inc (PHAT) | $492.63M | N/A | 1.8x | -30.2% | 11.4% | 71.1% | 0.00% |
| Rocket Pharmaceuticals Inc (RCKT) | $256.82M | N/A | N/A | 0.0% | -2.3% | 0.0% | 0.00% |
| Bicycle Therapeutics Ltd (BCYC) | $236.22M | N/A | 2.7x | -169.8% | N/A | 190.2% | 0.00% |
| Fate Therapeutics Inc (FATE) | $155.74M | N/A | 29.7x | 0.0% | -51.3% | 9.2% | 0.00% |
| Galectin Therapeutics Inc (GALT) | $307.59M | N/A | N/A | 0.0% | 671.1% | 0.0% | 0.00% |
| Lineage Cell Therapeutics Inc (LCTX) | $231.35M | N/A | 18.7x | 16.2% | -6.7% | -61.0% | 0.00% |
| Rezolute Inc (RZLT) | $353.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | $387.16M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $313.09M | 159.5x | 12.0x | 0.0% | -4.5% | 4.6% | 0.00% |
Similar Companies
These are the 12 companies most similar to Fulcrum Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| X4 Pharmaceuticals Inc (XFOR) | X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development... | XFOR competitors |
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
| Fennec Pharmaceuticals Inc (FENC) | Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. | FENC competitors |
| Phathom Pharmaceuticals Inc (PHAT) | Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. | PHAT competitors |
| Rocket Pharmaceuticals Inc (RCKT) | Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. | RCKT competitors |
| Bicycle Therapeutics Ltd (BCYC) | Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. | BCYC competitors |
| Fate Therapeutics Inc (FATE) | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. | FATE competitors |
| Galectin Therapeutics Inc (GALT) | Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic... | GALT competitors |
| Lineage Cell Therapeutics Inc (LCTX) | Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment... | LCTX competitors |
| Rezolute Inc (RZLT) | Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. | RZLT competitors |
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies... | CTNM competitors |
Frequently Asked Questions About FULC
Who are Fulcrum Therapeutics' main competitors?
The companies most similar to Fulcrum Therapeutics include X4 Pharmaceuticals (XFOR), Prelude Therapeutics (PRLD), Fennec Pharmaceuticals (FENC), Phathom Pharmaceuticals (PHAT) and Rocket Pharmaceuticals (RCKT), listed from the closest match.
Who is Fulcrum Therapeutics' biggest competitor?
Phathom Pharmaceuticals (PHAT) is the largest of the similar companies at $492.63M; X4 Pharmaceuticals (XFOR) is the closest match by business profile, size, sector and industry.
How does FULC stock compare with its competitors?
FULC's net margin is 0.0% against a peer median of 0.0%.
Which of Fulcrum Therapeutics' competitors pays a higher dividend?
Fulcrum Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Fulcrum Therapeutics bigger than its competitors?
No. Fulcrum Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Phathom Pharmaceuticals (PHAT) at $492.63M.
FULC pages: Overview, Earnings, Forecast, Financials, Competitors